聚甲基丙烯酸甲酯（Artecoll）作为面部重建的辅助手段2聚甲基丙烯酸甲酯（Artecoll）作为面部重建的辅助手段2聚甲基丙烯酸甲酯（Artecoll）作为面部重建的辅助手段2聚甲基丙烯酸甲酯（Artecoll）作为面部重建的辅助手段2聚甲基丙烯酸甲酯（Artecoll）作为面部重建的辅助手段2
At week 24, mean improvement in WSRS from baseline was 2.09 0.68 for the PLA side and 1.54 0.65 for the HA side. Both injections were well toler- ated, and the adverse reactions were mild and transient in most cases. PLA provides noninferior efficac
PLLA-induced augmentation is most likely based on capsule formation orchestrating macrophages, (myo-)fibroblasts, and collagen type I and III fibres. We observed considerably slower degradation of PLLA particles than described previously. Thus PLLA partic
Poly-L-lactic acid (PLLA) was approved for use in Europe in 1999. In the United States, it was approved by the Food and Drug Administration in 2004 for the treatment of facial lipoatrophy associated with human immunodeficiency virus, and in 2009 for cosm
